TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24337447
Drug: Autologous stem
Normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous stem cell transplantation (ASCT) after first-line therapy
Study: 24337447
Drug: Autologous stem
Normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous stem cell transplantation (ASCT) after second-line therapy
Study: 29354913
Drug: Auricular plaster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular plaster therapy
Study: 17717132
Drug: hsCRP >3
Approvals — FDA: no, EMA: no, PMDA: no
Description: hsCRP >3 mg/L in unstable angina/non-ST-elevation myocardial infarction (NSTEMI)
Study: 17717132
Drug: hsCRP >10
Approvals — FDA: no, EMA: no, PMDA: no
Description: hsCRP >10 mg/L in STEMI
Study: 9591496
Drug: Oral micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral micronized 17beta‐estradiol (2 mg/d) continuously combined with dydrogesterone (2.5 mg)
Study: 9591496
Drug: Oral micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral micronized 17beta‐estradiol (2 mg/d) continuously combined with dydrogesterone (5 mg)
Study: 9591496
Drug: Oral micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral micronized 17beta‐estradiol (2 mg/d) continuously combined with dydrogesterone (10 mg)
Study: 9591496
Drug: Oral micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral micronized 17beta‐estradiol (2 mg/d) continuously combined with dydrogesterone (15 mg)
Study: 7951368
Drug: Biken-Cam vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biken-Cam vaccine (5,000 TCID50/0.5 ml)
Study: 7951368
Drug: Edmonston-Zagreb vaccine
Normalized name: measles virus vaccine live, Enders' attenuated Edmonston strain
DrugBank: Measles virus vaccine live attenuated (DB10315)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edmonston-Zagreb vaccine with multiple puncture cylinder (7,000 TCID50/0.5 ml)
Study: 7951368
Drug: Edmonston-Zagreb vaccine
Normalized name: measles virus vaccine live, Enders' attenuated Edmonston strain
DrugBank: Measles virus vaccine live attenuated (DB10315)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edmonston-Zagreb vaccine with bifurcated needle (7,000 TCID50/0.5 ml)
Study: 29791259
Drug: Free cessation
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free cessation aids (nicotine-replacement therapy or pharmacotherapy, with e-cigarettes if standard therapies failed)
Study: 29791259
Drug: Free e-cigarettes
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Free e-cigarettes (without requirement that standard therapies had been tried)
Study: 10364999
Drug: Epidural diamorphine
Normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural diamorphine 5 mg
Study: 8254467
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of oral fluconazole once daily for 14 days
Study: 8254467
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg clotrimazole five times daily for 14 days
Study: 8254467
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of oral fluconazole once daily
Study: 8254467
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg clotrimazole five times daily
Study: 19857367
Drug: 48 g
Normalized name: GLYCERIN 3 g in 48 g CUTANEOUS OINTMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 48 g Resistant Starch (RS)
Study: 21574983
Drug: Briakinumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Briakinumab (200 mg at weeks 0 and 4, followed by 100 mg at week 8)
Study: 21574983
Drug: Etanercept (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (50 mg twice weekly at weeks 0-11)
Study: 16941367
Drug: 23-valent pneumococcal
Normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23-valent pneumococcal polysaccharide vaccine (PPV)
Study: 12698776
Drug: Contraceptive patch
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contraceptive patch (norelgestromin and ethinyl estradiol)
Study: 18238962
Drug: Contraceptive patch
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contraceptive patch
Study: 7030901
Drug: Calcium infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium infusion (35 mEq/5h)
Study: 1912107
Drug: Biperiden 2
Normalized name: biperiden 2 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biperiden 2 mg
Study: 1912107
Drug: Biperiden 4
Normalized name: biperiden 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biperiden 4 mg
Study: 31834098
Drug: Biperiden 2
Normalized name: biperiden 2 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biperiden 2 mg and 4 mg
Study: 31151335
Drug: Thoracic paravertebral
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic paravertebral block (PVB) with isobaric bupivacaine 0.5% (0.3 mL/kg) and dexmedetomidine (1 mcg/kg) - Group II
Study: 31151335
Drug: Thoracic paravertebral
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic paravertebral block (PVB) with isobaric bupivacaine 0.5% (0.3 mL/kg) - Group I
Study: 19499659
Drug: TIVA-TCI with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIVA-TCI with propofol (Cpi = 4 microg/ml) and remifentanil
Study: 17343103
Drug: New cardiovascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: New cardiovascular drugs without clinical trial outcome data
Study: 17343103
Drug: Similar drugs
Normalized name: Antigonadotropins and similar agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Similar drugs with clinical trial outcome data
Study: 9059545
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of oral losartan
Study: 8198030
Drug: Transdermal nitroglycerin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin, 0.6 mg/hour
Study: 10622071
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil 250 mg b.d.
Study: 3556123
Drug: Augmentin 375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentin 375 mg t.d.s.
Study: 3556123
Drug: Cefaclor 250
Normalized name: cefaclor 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor 250 mg t.d.s.
Study: 26182747
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment for peripheral vascular disease
Study: 26182747
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment for tibioperoneal lesions
Study: 26182747
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment for carotid lesions
Study: 18977243
Drug: Tailored Internet-plus-email
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored Internet-plus-email intervention (access to a tailored website and weekly emails)
Study: 31570509
Drug: Mass method
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass method of dosing epinephrine (milligrams per kilogram)
Study: 31570509
Drug: Volume method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume method of dosing epinephrine (milliliters per kilogram)
Study: 31570509
Drug: Mass method
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass method doses
Study: 31570509
Drug: Volume method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume method doses
Study: 17577112
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg hydrotalcite
Study: 2886245
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg famotidine
Study: 15726880
Drug: Itraconazole (Traconal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (Traconal 100 mg)
Study: 9797644
Drug: Postprandial lipaemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postprandial lipaemia and post‐heparin LPL activity
Study: 5443385
Drug: Intravenous pentazocine
Normalized name: Pentazocine
DrugBank: Pentazocine (DB00652)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous pentazocine 30 mg
Study: 5443385
Drug: Intravenous pentazocine
Normalized name: Pentazocine
DrugBank: Pentazocine (DB00652)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous pentazocine 60 mg
Study: 17214932
Drug: Non-Salvia miltiorrhiza
Normalized name: Salvia miltiorrhiza root extract
DrugBank: Salvia miltiorrhiza root (DB14337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-Salvia miltiorrhiza treatment
Study: 15019333
Drug: Control (observation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (observation and laser treatment)
Study: 11352445
Drug: Probenecid 500mg
Normalized name: PROBENECID 500MG TAB
DrugBank: Probenecid (DB01032)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Probenecid 500mg twice daily for 2 days before moxifloxacin
Study: 9165133
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with cisplatin (100 mg/m2 i.v. infusion on day 1) and 5-fluorouracil (1000 mg/m2 continuous i.v. infusion for 120 hours) followed by radiotherapy (64-70 Gy in 2 Gy per fraction, 5 times/week)
Study: 9165133
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (radiotherapy or radiotherapy followed by surgery)
Study: 9165133
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with cisplatin and 5-fluorouracil followed by radiotherapy
Study: 7970935
Drug: L-[2-15N]glutamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-[2-15N]glutamine infusion
Study: 7970935
Drug: L-[1-13C]leucine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-[1-13C]leucine infusion
Study: 24595568
Drug: Topical clofibrate
Normalized name: Clofibrate
DrugBank: Clofibrate (DB00636)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical clofibrate
Study: 18245032
Drug: Olanzapine plus
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine plus carbamazepine (10-30 mg/day plus 400-1200 mg/day)
Study: 18245032
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus carbamazepine (400-1200 mg/day)
Study: 11969360
Drug: Cefuroxime (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime (100 mg/kg/day) IV
Study: 11969360
Drug: Dicloxacillin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dicloxacillin (200 mg/kg/day) plus Chloramphenicol (100 mg/kg/day) IV
Study: 12422059
Drug: Paroxetine (20-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20-30 mg/day)
Study: 10401446
Drug: Nortriptyline (adjusted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline (adjusted to plasma concentration of 50-150 ng/ml)
Study: 7240807
Drug: Subvirion influenza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subvirion influenza B vaccine (500 chick cell‐agglutinating units)
Study: 7240807
Drug: Whole‐virus influenza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole‐virus influenza B vaccine
Study: 7240807
Drug: Subvirion influenza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subvirion influenza B vaccine
Study: 30591465
Drug: FOLFIRI with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI with 100 mg erlotinib daily on days 3-8 after each infusion every 14 days
Study: 30591465
Drug: mFOLFOX6 with
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOX6 with 100 mg erlotinib daily on days 3-8 after each infusion every 14 days
Study: 24433926
Drug: IFNβ‐1a i.m.
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNβ‐1a i.m. weekly injected (group a)
Study: 24433926
Drug: IFNβ‐1a 44
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNβ‐1a 44 μg s.c. injected three times a week (group b)
Study: 19056572
Drug: FS50 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: FS50 (50 g/day, 264 kcal)
Study: 19056572
Drug: LP (maize-soy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LP (maize-soy flour, 71 g/day, 282 kcal)
Study: 19056572
Drug: FS25 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: FS25 (25 g/day, 130 kcal)
Study: 21934487
Drug: Endovenous laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovenous laser therapy (EVLT)
Study: 16802211
Drug: Endovenous laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovenous laser therapy (EVLT) and Surgery
Study: 29803534
Drug: Nemonoxacin 500
Normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemonoxacin 500 mg (therapeutic dose)
Study: 29803534
Drug: Nemonoxacin 750
Normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemonoxacin 750 mg (supratherapeutic dose)
Study: 29803534
Drug: Nemonoxacin 500
Normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemonoxacin 500 mg after high-fat food intake
Study: 29803534
Drug: Nemonoxacin (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemonoxacin (both doses)
Study: 27299459
Drug: Xuefu Zhuyu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuefu Zhuyu Capsule (XFZY-CS) at 2.5% concentration
Study: 27299459
Drug: Xuefu Zhuyu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuefu Zhuyu Capsule (XFZY-CS) at 5% concentration
Study: 19557206
Drug: Montelukast as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast as add-on therapy
Study: 17577134
Drug: Methylprednisolone 500
Normalized name: methylprednisolone 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 500 mg preoperatively
Study: 16354313
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (n=142; 4 cycles of cisplatin 75 mg/m2 I.V. on day 1 with etoposide 100 mg/m2 I.V. on days 1-3 followed by 4 cycles of topotecan 1.5 mg/m2 I.V. on days 1-5)
Study: 16354313
Drug: Alternating therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating therapy (n=142; same doses of cisplatin/etoposide on cycles 1, 3, 5, and 7 and topotecan on cycles 2, 4, 6, and 8)
Study: 10434322
Drug: Group 3:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3: Planned consultation and test injection before surgery
Study: 2277574
Drug: Diphenylhydantoin (DPH)
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diphenylhydantoin (DPH) 2.5 mg kg‐1
Study: 7026817
Drug: Preferred medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preferred medication
Study: 11346831
Drug: Extracorporeal shockwave
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shockwave therapy (ESWT) plus manual therapy of the cervical spine (group I)
Study: 11346831
Drug: Low-energy shockwave
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-energy shockwave therapy (group II)
Study: 7822903
Drug: Hydroxyethylrutosides (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethylrutosides (1 g twice daily for 4 weeks)
Study: 3126638
Drug: NTG oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTG oral spray (0.8 mg) in hydrosoluble solution (NTG-h)
Study: 3126638
Drug: NTG oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTG oral spray (0.8 mg) in liposoluble solution (NTG-I)
Study: 3126638
Drug: NTG oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTG oral spray (both formulations)
Study: 11467238
Drug: Acetazolamide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (250 mg)
Study: 14520129
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (Imipramine, Buspirone, Placebo)
Study: 7899651
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (0.5 mg) in Group C0.5
Study: 7899651
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (0.5 mg) in Group A0.5
Study: 7899651
Drug: Subcutaneous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous morphine in Group C0
Study: 7899651
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (0.5 mg) in Groups C0.5 and A0.5
Study: 7933485
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (0.5 mg)
Study: 2693031
Drug: Triflusal (platelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triflusal (platelet antiaggregant drug)
Study: 31421670
Drug: MOFA (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOFA (0.2 g/kg fish oil preoperatively, followed by 48 h continuous infusion of 0.2 g/kg/d n3FA)
Study: 31421670
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard ERAS therapy)
Study: 27893184
Drug: Antidepressants and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants and antipsychotics (specific drugs not detailed)
Study: 27893184
Drug: Psychotropic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotropic drugs with cardiovascular risk
Study: 15694243
Drug: Psychotropic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotropic drugs
Study: 27893184
Drug: Risk drugs
Normalized name: Hep B, adolescent/high risk infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk drugs
Study: 27090863
Drug: Corifollitropin alfa
Normalized name: corifollitropin alfa
DrugBank: Corifollitropin alfa (DB09066)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Corifollitropin alfa (150 μg single injection)
Study: 26003273
Drug: Recombinant FSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant FSH (300 IU daily for first 7 days, then daily until three follicles reach ≥17 mm)
Study: 23880960
Drug: Aspirin 600
Normalized name: aspirin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 600 mg/day
Study: 23880960
Drug: Resistant starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistant starch 30 g/day
Study: 23880960
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no aspirin or resistant starch)
Study: 20659577
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with formoterol (FOR) 12 μg BID plus tiotropium (TIO) 18 μg QD
Study: 20659577
Drug: Tiotropium (TIO)
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium (TIO) alone 18 μg QD
Study: 19812401
Drug: Doxycycline 200
Normalized name: doxycycline 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 200 mg daily for 6 weeks
Study: 12970329
Drug: Simvastatin 80
Normalized name: simvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 80 mg daily
Study: 17967584
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 2 mg plus vitamin B12 1 mg daily
Study: 2188379
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg daily
Study: 15479217
Drug: Gliclazide MR
Normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide MR (30-120 mg) once daily
Study: 15479217
Drug: Gliclazide MR
Normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide MR in combination therapy
Study: 11242646
Drug: High-dose group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose group: MMC at 8 mg/m2 on the day of surgery, and in weeks 4, 10, 16, and 22 after surgery; 6 capsules of UFT (600 mg in tegafur) daily for 6 months.
Study: 11242646
Drug: Low-dose group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose group: MMC at 8 mg/m2 on the day of surgery; 3 capsules of UFT (300 mg in tegafur) daily for 6 months.
Study: 16808624
Drug: High-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose group
Study: 1977079
Drug: Low-dose group
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose group
Study: 7996525
Drug: Programmable subcutaneous
Normalized name: PUMP,LUTREPULSE PROGRAMMABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Programmable subcutaneous infusion pump with terbutaline, adjusted to control uterine contraction frequency to < or = 4 contractions per hour.
Study: 7996525
Drug: Oral terbutaline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terbutaline, average of 6.5 mg every four to six hours.
Study: 3396249
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate (100 mg IM bi-weekly for six months)
Study: 31356008
Drug: Serenoa repens
Normalized name: Serenoa Repens Fruit
DrugBank: Saw palmetto (DB14360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serenoa repens extract (ESR - Permixon) 320 mg capsules per day for two years
Study: 24012053
Drug: 5-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day course of amoxicillin/clavulanic acid 625 mg orally every 8 h for 4 days after 24 h of intravenous administration
Study: 24012053
Drug: 1-day course
Normalized name: ESTRADIOL BENZOATE 1 kg in 1 kg POWDER [Estradiol Benzoate Coarse Grade]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-day course of amoxicillin/clavulanic acid 1.2 g intravenously for 24 h followed by oral placebo
Study: 15000513
Drug: Acamprosate (1.998
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acamprosate (1.998 mg/day)
Study: 7908821
Drug: discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: discontinuation of both anaesthetics
Study: 22696144
Drug: Group LM
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group LM (19 ml of 0.25% levobupivacaine and 1 ml of 15% magnesium sulphate)
Study: 22696144
Drug: Group L
Normalized name: Blood group Lewis alpha-4-fucosyltransferase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group L (20 ml of 0.25% levobupivacaine)
Study: 17937959
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg fesoterodine
Study: 17937959
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg fesoterodine
Study: 15731540
Drug: Mucosal protection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mucosal protection (teprenone 150 mg/day)